David C. Sachs - Dec 31, 2022 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Chief Financial Officer
Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Stock symbol
IBRX
Transactions as of
Dec 31, 2022
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 08:49 PM
Previous filing
Mar 25, 2022
Next filing
Aug 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +7.6K +17.39% $0.00 51.3K Dec 31, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -7.6K -5.26% $0.00 137K Dec 31, 2022 Common Stock 7.6K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.